Avidity Partners Management LP Bellus Health Inc. Transaction History

Avidity Partners Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.14 - $8.53 $331,445 - $395,971	-46,421 Reduced 1.01%	4,553,577 $32.8 Million
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $2.08 Million - $2.73 Million	253,298 Added 5.83%	4,599,998 $37.8 Million
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $731,215 - $980,400	81,700 Added 1.92%	4,346,700 $45.9 Million
Q2 2022 Aug 15, 2022	BUY	$6.46 - $10.02 $3.75 Million - $5.81 Million	580,000 Added 15.74%	4,265,000 $39.4 Million
Q1 2022 May 16, 2022	SELL	$5.56 - $7.99 $500,399 - $719,100	-90,000 Reduced 2.38%	3,685,000 $25.4 Million
Q4 2021 Feb 14, 2022	SELL	$5.26 - $8.3 $6.14 Million - $9.69 Million	-1,167,000 Reduced 23.61%	3,775,000 $30.4 Million
Q3 2021 Nov 15, 2021	BUY	$2.7 - $6.64 $1.87 Million - $4.59 Million	692,000 Added 16.28%	4,942,000 $30.3 Million
Q2 2021 Aug 16, 2021	SELL	$3.11 - $4.61 $7.92 Million - $11.7 Million	-2,547,400 Reduced 37.48%	4,250,000 $13.2 Million
Q1 2021 May 17, 2021	BUY	$3.03 - $4.58 $3.25 Million - $4.91 Million	1,071,400 Added 18.71%	6,797,400 $26.1 Million
Q4 2020 Feb 16, 2021	BUY	$2.27 - $3.3 $13 Million - $18.9 Million	5,726,000 New	5,726,000 $17.5 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.